---
pmid: '26267534'
title: Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK
  Pathway Oncogenes.
authors:
- Herrero A
- Pinto A
- Colón-Bolea P
- Casar B
- Jones M
- Agudo-Ibáñez L
- Vidal R
- Tenbaum SP
- Nuciforo P
- Valdizán EM
- Horvath Z
- Orfi L
- Pineda-Lucena A
- Bony E
- Keri G
- Rivas G
- Pazos A
- Gozalbes R
- Palmer HG
- Hurlstone A
- Crespo P
journal: Cancer Cell
year: '2015'
full_text_available: false
doi: 10.1016/j.ccell.2015.07.001
---

# Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.
**Authors:** Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P
**Journal:** Cancer Cell (2015)
**DOI:** [10.1016/j.ccell.2015.07.001](https://doi.org/10.1016/j.ccell.2015.07.001)

## Abstract

1. Cancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK 
Pathway Oncogenes.

Herrero A(1), Pinto A(1), Colón-Bolea P(1), Casar B(1), Jones M(2), Agudo-Ibáñez 
L(1), Vidal R(3), Tenbaum SP(4), Nuciforo P(4), Valdizán EM(3), Horvath Z(5), 
Orfi L(6), Pineda-Lucena A(7), Bony E(8), Keri G(9), Rivas G(10), Pazos A(3), 
Gozalbes R(11), Palmer HG(4), Hurlstone A(12), Crespo P(13).

Author information:
(1)Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo 
Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, 
Santander 39011, Spain.
(2)Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK.
(3)Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo 
Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, 
Santander 39011, Spain; Departamento de Fisiología y Farmacología, Centro de 
Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud 
Carlos III Universidad de Cantabria, Santander 39011, Spain.
(4)Stem Cells and Cancer Laboratory, Translational Research Program, Vall 
d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
(5)Vichem Chemie Research Ltd., 1022 Budapest, Hungary.
(6)Vichem Chemie Research Ltd., 1022 Budapest, Hungary; Department of 
Pharmaceutical Chemistry, Semmelweis University, 1092 Budapest, Hungary.
(7)Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.
(8)Pharmacognosy Research Group, Louvain Drug Research Institute, Université 
Catholique de Louvain, 1200 Bruxelles, Belgium.
(9)Vichem Chemie Research Ltd., 1022 Budapest, Hungary; MTA-SE Pathobiochemistry 
Research Group, Department of Medical Chemistry, Semmelweis University, 1092 
Budapest, Hungary.
(10)Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones 
Científicas, 28040 Madrid, Spain.
(11)ProtoQSAR S.L., 46008 Valencia, Spain.
(12)Departamento de Fisiología y Farmacología, Centro de Investigación Biomédica 
en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de 
Cantabria, Santander 39011, Spain.
(13)Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo 
Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, 
Santander 39011, Spain. Electronic address: crespop@unican.es.

Comment in
    Cancer Cell. 2015 Aug 10;28(2):145-7. doi: 10.1016/j.ccell.2015.07.008.
    Nat Rev Cancer. 2015 Oct;15(10):574-5. doi: 10.1038/nrc4011.

Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; 
inhibiting it is a valid strategy for antineoplastic intervention. Upon 
activation, ERK dimerize, which is essential for ERK extranuclear, but not for 
nuclear, signaling. Here, we describe a small molecule inhibitor for ERK 
dimerization that, without affecting ERK phosphorylation, forestalls 
tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected 
by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, 
ERK dimerization inhibitors provide the proof of principle for two understudied 
concepts in cancer therapy: (1) the blockade of sub-localization-specific 
sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK 
signaling and (2) targeting regulatory protein-protein interactions, rather than 
catalytic activities, as an approach for producing effective antitumor agents.

Copyright © 2015 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2015.07.001
PMID: 26267534 [Indexed for MEDLINE]
